Significance of detectable hepatitis B virus DNA in liver allograft tissue in long-term follow-up of liver transplant recipients.

Hepatitis B virus liver failure liver transplantation

Journal

Hepatology forum
ISSN: 2757-7392
Titre abrégé: Hepatol Forum
Pays: Turkey
ID NLM: 9918351171306676

Informations de publication

Date de publication:
May 2021
Historique:
received: 11 02 2021
accepted: 19 03 2021
entrez: 5 7 2022
pubmed: 21 5 2021
medline: 21 5 2021
Statut: epublish

Résumé

The objective of this study was to evaluate the long-term presence of hepatitis B virus (HBV) DNA in the liver grafts of liver transplant patients who received hepatitis B immunoglobulin (HBIg) plus oral antiviral hepatitis B virus prophylaxis and had negative HBV serum markers. Patients aged 18 years or older who underwent liver transplantation for HBV-related liver disease, had negative serum viral markers, and had a liver biopsy at least 3 years after liver transplantation were eligible for this study. Clinical, serological, and pathological data were retrospectively obtained from medical records. The HBV DNA of liver biopsy specimens was assessed using the polymerase chain reaction technique. A total of 150 patients were included. A positive HBV DNA result was seen in 18 (12%) of the liver biopsies. The presence of intrahepatic HBV DNA was not associated with pre-transplantation serum viral markers, type of pre- or post-transplantation antiviral treatment, or post-transplantation immunosuppressive treatment. The findings suggest that while treatment with HBIg plus oral antiviral as post-transplantation HBV prophylaxis may result in a percentage of patients with persistent HBV DNA in the graft, the presence of HBV DNA in the liver graft may not be related to clinical HBV recurrence.

Sections du résumé

Background and Aim UNASSIGNED
The objective of this study was to evaluate the long-term presence of hepatitis B virus (HBV) DNA in the liver grafts of liver transplant patients who received hepatitis B immunoglobulin (HBIg) plus oral antiviral hepatitis B virus prophylaxis and had negative HBV serum markers.
Materials and Methods UNASSIGNED
Patients aged 18 years or older who underwent liver transplantation for HBV-related liver disease, had negative serum viral markers, and had a liver biopsy at least 3 years after liver transplantation were eligible for this study. Clinical, serological, and pathological data were retrospectively obtained from medical records. The HBV DNA of liver biopsy specimens was assessed using the polymerase chain reaction technique.
Results UNASSIGNED
A total of 150 patients were included. A positive HBV DNA result was seen in 18 (12%) of the liver biopsies. The presence of intrahepatic HBV DNA was not associated with pre-transplantation serum viral markers, type of pre- or post-transplantation antiviral treatment, or post-transplantation immunosuppressive treatment.
Conclusion UNASSIGNED
The findings suggest that while treatment with HBIg plus oral antiviral as post-transplantation HBV prophylaxis may result in a percentage of patients with persistent HBV DNA in the graft, the presence of HBV DNA in the liver graft may not be related to clinical HBV recurrence.

Identifiants

pubmed: 35783904
doi: 10.14744/hf.2021.2021.0003
pii: hf-2-43
pmc: PMC9138924
doi:

Types de publication

Journal Article

Langues

eng

Pagination

43-48

Informations de copyright

© Copyright 2021 by Hepatology Forum - Available online at www.hepatologyforum.org.

Déclaration de conflit d'intérêts

Conflict of Interest: The authors have no conflict of interest to declare.

Références

J Hepatol. 1999 Apr;30(4):715-21
pubmed: 10207815
Transplantation. 1990 Jun;49(6):1155-8
pubmed: 2360255
Gastroenterology. 2008 Jun;134(7):1890-9; quiz 2155
pubmed: 18424269
J Clin Transl Hepatol. 2016 Mar 28;4(1):54-65
pubmed: 27047773
J Med Virol. 1990 Aug;31(4):312-7
pubmed: 2269882
Immunol Rev. 2000 Apr;174:98-111
pubmed: 10807510
Liver Transpl. 2005 Apr;11(4):402-9
pubmed: 15776431
Gastroenterology. 1988 Jan;94(1):151-6
pubmed: 3275563
Hepatology. 1996 Dec;24(6):1327-33
pubmed: 8938155
Hepatology. 2003 Jul;38(1):86-95
pubmed: 12829990
J Hepatol. 2001 Jun;34(6):903-10
pubmed: 11451175
World J Hepatol. 2018 Mar 27;10(3):352-370
pubmed: 29599899
Br Med J (Clin Res Ed). 1984 May 26;288(6430):1563-6
pubmed: 6426645
Gastroenterology. 2015 Jan;148(1):221-244.e3
pubmed: 25447852
Hepatology. 1990 Aug;12(2):364-6
pubmed: 2202639
J Hepatol. 2012 May;56(5):1189-1197
pubmed: 22274310
Hepatology. 1993 Oct;18(4):781-9
pubmed: 8406351
Liver Transpl. 2007 Aug;13(8):1137-44
pubmed: 17663390
Am J Pathol. 1986 Oct;125(1):161-72
pubmed: 3535528
Dig Liver Dis. 2010 Aug;42(8):578-84
pubmed: 20097143
Hepatology. 1995 Jul;22(1):36-43
pubmed: 7601429

Auteurs

Deniz Mut Surmeli (D)

Department of Geriatrics, Ankara University School of Medicine, Ankara, Turkey.

Ilker Turan (I)

Department of Gastroenterology, Ege University School of Medicine, Izmir, Turkey.

Sinan Akay (S)

Department of Gastroenterology, Kutahya University of Health Sciences, Kutahya, Turkey.

Selda Erensoy (S)

Department of Microbiology and Clinical Microbiology, Ege University School of Medicine, Izmir, Turkey.

Galip Ersoz (G)

Department of Gastroenterology, Ege University School of Medicine, Izmir, Turkey.

Fulya Gunsar (F)

Department of Gastroenterology, Ege University School of Medicine, Izmir, Turkey.

Ulus Akarca (U)

Department of Gastroenterology, Ege University School of Medicine, Izmir, Turkey.

Zeki Karasu (Z)

Department of Gastroenterology, Ege University School of Medicine, Izmir, Turkey.

Classifications MeSH